BU-NOT-SET

CONTACT US
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
  • Drug substance
Man at poster
Poster
Recipharm Analytical Solutions™
  • Analytical chemistry
Icon
Fact sheet
Impurity identification
  • Analytical chemistry
Woman inserting vials in machine
Fact sheet
Stability studies
  • Analytical chemistry
hand holding vials plate
Fact sheet
Extractables & leachables testing
  • Analytical chemistry
Product mix
Fact sheet
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
  • Industry trends
Eyes
Insight
Global expansion in the CDMO field
  • Industry trends
Eyes
Insight
Fixed dose combinations - for improved patient compliance
  • Drug product
mini-tablets
Fact sheet
The current state of contract manufacturing
  • Industry trends
Eyes
Insight
Insight
  • Manufacturing
Is outsourcing the most viable pathway for innovators?
Case study
  • Drug product
Developing a generic prolonged-release isosorbide-5-mononitrate tablet
Insight
  • Industry trends
Recipharm Wins two 2020 CMO Leadership Awards
Insight
  • Corporate
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
Insight
  • Manufacturing
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
Brochure
  • Corporate
Recipharm 25 years
Fact sheet
  • Drug substance
API product list
Insight
  • Drug substance
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
Insight
  • Industry trends
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19